This is a working overview of visceral adipose tissue, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-18. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
== Composition == Petroleum consists of a variety of liquid, gaseous, and solid components. Lighter hydrocarbons are the gases methane, ethane, propane and butane. Otherwise the bulk of the liquid and solids are largely heavier organic compounds, often hydrocarbons (C and H only). The proportion of light hydrocarbons in a petroleum mixture varies among oil fields. An oil well produces predominantly crude oil. Because the pressure is lower at the surface than underground, some of the gas will come out of solution and be recovered (or burned) as associated gas or solution gas. A gas well produces predominantly natural gas. However, because the underground temperature is higher than at the surface, the gas may contain heavier hydrocarbons such as pentane, hexane, and heptane ("natural-gas condensate", often shortened to condensate.) Condensate resembles gasoline in appearance and is similar in composition to some volatile light crude oils. The hydrocarbons in crude oil are mostly alkanes, cycloalkanes and various aromatic hydrocarbons, while the other organic compounds contain nitrogen, oxygen, and sulfur, and traces of metals such as iron, nickel, copper and vanadium. Many oil reservoirs contain live bacteria. The molecular composition of crude oil varies widely from formation to formation, but the proportion of chemical elements varies over fairly narrow limits as follows:
Robert John Shiach, Cattleman. For services to the Cattle Industry in Banffshire. William Shiel. For services to Tourism in Northumbria. Trevor Royston Shore, Instructor/Examiner, Dorset County Council Cycle Training Scheme. For services to Road Safety. Joan Silcox. For charitable services in Newcastle-upon-Tyne. Annie Mary Simpson. For services to Education. Sylvia Yvonne Simpson. For services to the Police. Jean Skinner, School Crossing Patrol Warden, Kent County Council. For services to Road Safety. Robert Skinner. For services to the St Andrew's Ambulance Association. David Slater. For services to the community in Worksop Nottinghamshire. Eileen Lorraine Smart, Administrative Assistant, Department of Trade and Industry. Gwenneth Maude Muriel Smewin, lately Headteacher, Dunmore County Infants School, Abingdon, Oxfordshire. For services to Education. Barbara Antoinette Smith, Senior Nurse Manager, Leicester General Hospital. For services to Health Care. Brenda Smith. For charitable services. Carol Beverley Smith, Motor Transport Driver, Ministry of Defence. Graham Arthur Smith, Engineering Manager, Secure Products, Siemens Plessey Systems Ltd. For services to Defence Technology. John McCrindle Smith, . For services to the Magistracy and to the Police Committee in Essex. The Reverend Canon John Reginald Smith. For services to the community in Bury, Greater Manchester. Pauline Smith. For services to the Citizens' Advice Bureau in Sale, Cheshire. Thomas Robert Smith. For services to the community in High Wycombe, Buckinghamshire. Stuart Alan Spears.
=== High aldosterone levels === Spironolactone is used in the treatment of hyperaldosteronism (high aldosterone levels or mineralocorticoid excess), for instance primary aldosteronism (Conn's syndrome). Antimineralocorticoids including spironolactone and eplerenone are first-line treatments for hyperaldosteronism. They improve blood pressure and potassium levels, as well as left ventricular hypertrophy, albuminuria, and carotid intima-media thickness, in people with primary aldosteronism. In people with hyperaldosteronism due to unilateral aldosterone-producing adrenocortical adenoma, adrenalectomy should be preferred instead of antimineralocorticoids. Spironolactone should not be used to treat primary aldosteronism in pregnancy due to its antiandrogen-related risk of teratogenicity in male fetuses.
=== 4 May === Explosions were reported in Kyiv and Odesa in another series of Russian air attacks. Ukraine claimed to have destroyed 18 out of the 24 drones launched, plus a reconnaissance drone, with only light damage to property; the drones were marked with messages such as "For Moscow" and "For the Kremlin". According to TASS, Ukrainian drones attacked and set ablaze the Ilsky refinery near Novorossiisk. The fire was extinguished without damage after two hours. Fighting broke out between Russian and Ukrainian delegates to the Parliamentary Assembly of the Black Sea Economic Cooperation in Ankara, Turkey. Ukrainian delegates had earlier waved Ukrainian flags during a speech by a Russian delegate. Later, Oleksandr Marikovski, a Ukrainian MP, physically assaulted a Russian official after the latter seized his flag. Ukraine for the first time intercepted a Russian Kh-47M2 Kinzhal hypersonic missile, following reports from Kyiv of a powerful explosion overnight. The Ukrainian Air Force said they shot it down using the Patriot missile system protecting the capital.
Sources: en.wikipedia.org
=== Supply Chain Magazines === In September 2022, ISCEA Indonesia released Supply Chain Insights, a virtual magazine intended to share information and knowledge among Indonesian supply chain professionals. In April 2024, the Global "Sustainable Supply Chain" Magazine was released with Ushasi Segupta as Editor in Chief and Madison DeSilva as Publisher. In 2025, Dr. Mahmoud Mansi, an award-winning author of 9 books and Advisory Board Member at ISCEA, was appointed Editor in Chief of ISCEA's "Supply Chain Journal Middle East".
==== PEG treatment ==== The purpose of the polyethylene glycol is to remove water from the wood while simultaneously bulking the deteriorated wood cells. PEG is applied to the surface, either by spraying or immersing the object in a solution of PEG in water. Over the course of the treatment, PEG is slowly increased in concentration, pushing out the excess water, coating the interior walls of the wood cells with PEG, which, depending on the molecular weight selected, will provide support once the artifact is dried. PEG compounds with different molecular weights may be used depending on the wood type, level of deterioration, and scope of project. The PEG treatment is often paired with vacuum freeze-drying, as the eutectic point of most PEG solutions is below the freezing point of water. This allows the "free" waterlogging water to sublimate in the process of freeze-drying, which minimizes damage to the wood by preventing ice from forming within the cells and expanding, causing more shrinking and warping. Some artifacts are too large to fit in a commercially available freeze-drier (see the treatment for Vasa or Mary Rose or the Bremen cog).
== Prevention == There is ongoing research for methods to prevent type 1 diabetes. The development of diabetes symptoms can be delayed in some people who are at high risk of developing the disease. In 2022, the FDA approved an intravenous injection of teplizumab to delay the progression of type 1 diabetes in those older than eight who have already developed diabetes-related autoantibodies and problems with blood sugar control. In that population, the anti-CD3 monoclonal antibody teplizumab can delay the development of type 1 diabetes symptoms by around two years. In addition to anti-CD3 antibodies, several other immunosuppressive agents have been trialled to prevent beta cell destruction. Large trials of cyclosporine treatment suggested that cyclosporine could improve insulin secretion in those recently diagnosed with type 1 diabetes; however, people who stopped taking cyclosporine rapidly stopped making insulin, and cyclosporine's kidney toxicity and increased risk of cancer prevented people from using it long-term. Several other immunosuppressive agents – prednisone, azathioprine, anti-thymocyte globulin, mycophenolate, and antibodies against CD20 and IL2 receptor α – have been the subject of research. None has provided lasting protection from the development of type 1 diabetes. There have also been clinical trials attempting to induce immune tolerance by vaccination with insulin, GAD65, and various short peptides targeted by immune cells during type 1 diabetes; none have yet delayed or prevented development of disease.
== Season 6 (2020) == Season 6 is themed around a haunted house. Carla Hall acts as both a judge and the host, leading the contestants on a tour of a different themed room in each episode. Unlike other seasons, the first six episodes of this season each contained only one challenge.
== Education and career == Nguyen received an undergraduate degree in chemistry from Imperial College London, followed by a master's degree in health policy, planning and finance London School of Economics and from the London School of Hygiene and Tropical Medicine (LSHTM). She worked for the World Health Organization where she conducted research on medical policies. Between 1999 and 2010, she worked at GlaxoSmithKline and led the development of policies on access to medications and vaccines in the developing world. She joined Gavi in 2011, where she worked find ways to support financially sustainable vaccine programs and markets, and notably worked on strategies to supply Ebola vaccines and HPV vaccines against cervical cancer to developing countries. In October 2020, she was appointed managing director of the Office of the COVAX Facility. In 2021, Nguyen was selected as a Bloomberg New Economy Catalyst. As part of the program, Aurelia attended the annual New Economy Forum held in Singapore, and the Bloomberg New Economy Catalyst Retreat that same year.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.